Needham & Company Reiterates Buy on Progenics Pharma (PGNX); Anticipates Oral Relistor Approval

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 11/3/2026

1. AAPL
2. PLTR
3. VRTX
4. CHKP
5. ON
6. CRWD
7. HNGE
8. INSP
9. MRVL
10. MTCH

Go back to Needham & Company Reiterates Buy on Progenics Pharma (PGNX); Anticipates Oral Relistor Approval

Progenics Pharmaceuticals Announces Fourth Quarter and Full-Year 2015 Financial and Business Results

March 11, 2016 8:00 AM EST

RELISTOR® Net Sales Increased to $23.0 Million for the Fourth Quarter Oral RELISTOR Remains On-track for April 19, 2016 PDUFASubcutaneous RELISTOR Approved in Europe for All Opioid-Induced ConstipationAZEDRA® Ultra-Orphan Cancer Therapeutic Receives FDA Breakthrough DesignationAZEDRA Completes Enrollment of 68 Patients in Pivotal Trial and Topline Results Expected Between December 2016 and March 2017Initiated Pivotal Phase 3 Study of 1404, PSMA-Targeted SPECT/CT Imaging Agent Clinical Studies Planned for PyL PSMA-Targeted PET/CT Imaging Agent Licensed... More